BI 771716 for Age-Related Macular Degeneration

This trial explores how different doses of BI 771716 are tolerated by individuals with geographic atrophy, a severe form of age-related macular degeneration (AMD) that affects vision. Participants will receive injections of BI 771716 in the eye to assess their response to the treatment. This study marks the first time this medicine is tested on humans. Individuals with geographic atrophy due to AMD, whose vision is better in one eye than the other, might be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol mentions a medication washout period, which means you may need to stop taking certain medications before participating. However, it does not specify which medications are affected, so it's best to discuss this with the trial doctors.

Research has shown that BI 771716 has been safely tested in both single and multiple doses. In earlier studies, this treatment met its main safety goals when administered as eye injections, indicating it was well-tolerated by recipients.

Although this trial marks the first time BI 771716 is tested in humans, previous research provides some reassurance about its safety. The treatment is part of an antibody specifically designed to target the condition.

Unlike the standard treatments for age-related macular degeneration, which often involve anti-VEGF injections, BI 771716 offers a novel approach by potentially targeting a different pathway to slow or stop the progression of the disease. This treatment is unique because it explores varying doses, from low to high, to assess the optimal therapeutic effect. Researchers are particularly excited about BI 771716 as it may provide an alternative for patients who do not respond well to existing therapies, offering hope for improved vision outcomes and quality of life.

Research has shown that BI 771716 may help treat geographic atrophy, a severe form of age-related macular degeneration. Early results from similar studies have been positive, suggesting that this treatment might slow the condition's progression. BI 771716 targets specific proteins in the eye that cause vision loss. In this trial, participants will receive different doses of BI 771716 to assess its effectiveness and safety. Although this is the first human trial for BI 771716, earlier research has been promising, indicating potential benefits in managing the condition.¹²³⁴⁶